Showing results (41-50 of 110) with videos related to
Sort By:
Pageof 11
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|October 25, 2022
Real-world treatment patterns, costs, and outcomes in patients with AL amyloidosis: analysis of the Optum EHR and commercial claims databasesAngela Dispenzieri, Jeffrey Zonder, James Hoffman, et al.American Journal of Hematology|June 26, 2012
Absolute lymphocyte count at day 28 independently predicts event-free and overall survival in adults with newly diagnosed acute lymphoblastic leukemiaDi Sun, Paul Elson, Michaela Liedtke, et al.Cancer|January 31, 2018
Efficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INO-VATEElias J Jabbour, Daniel J DeAngelo, Matthias Stelljes, et al.Haematologica|December 18, 2012
Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemiaDaniel A Pollyea, James Zehnder, Steve Coutre, et al.Cancer|March 29, 2019
Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE studyHagop M Kantarjian, Daniel J DeAngelo, Matthias Stelljes, et al.Blood Cancer Journal|August 10, 2020
Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burdenDaniel J DeAngelo, Anjali S Advani, David I Marks, et al.The New England Journal of Medicine|June 14, 2016
Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic LeukemiaHagop M Kantarjian, Daniel J DeAngelo, Matthias Stelljes, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 10, 2016
First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ DysfunctionMorie A Gertz, Heather Landau, Raymond L Comenzo, et al.Leukemia Research|December 3, 2019
Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trialElias Jabbour, Nicola Gökbuget, Anjali Advani, et al.Nature Biotechnology|December 4, 2019
Single-cell multiomic analysis identifies regulatory programs in mixed-phenotype acute leukemiaJeffrey M Granja, Sandy Klemm, Lisa M McGinnis, et al.Pageof 11